腺癌

化疗

铂类: Cisplatin; Carboplatin; Nedaplatin

生物碱类: Vinorelbine ditartrate; Paclitaxel; Docetaxel

抗代谢类: Pemetrexed; Gemcitabine

拓扑异构酶抑制剂: Irinotecan

靶向-RET

选择性RET抑制剂: Selpercatinib; Pralsetinib

非选择性RET抑制剂: Cabozantinib; Vandetanib; Lenvatinib; Regorafenib

靶向-BRAF

一代(I型)BRAF抑制剂: Vemurafenib; Dabrafenib; Encorafenib

二代(I型)BRAF抑制剂: AZ 628; LY3009120

靶向-ROS1

一代ROS1-TKIs: Crizotinib

二代ROS1-TKIs: Ceritinib; Repotrectinib

三代ROS1-TKIs: Lorlatinib

靶向-MET

I型MET-TKIs: Crizotinib; Capmatinib; Tepotinib; Savolitinib

II型MET-TKIs: Cabozantinib; Merestinib

III型MET-TKIs: Tivantinib

靶向-KRAS G12C

Sotorasib

Adagrasib

MRTX-1257

ARS-1620

Divarasib

靶向-ALK

一代ALK-TKIs: Crizotinib

二代ALK-TKIs: Ceritinib; Alectinib; Brigatinib; Ensartinib dihydrochloride

三代ALK-TKIs: Lorlatinib

靶向-EGFR

一代EGFR-TKIs: Erlotinib; Gefitinib; Lapatinib; Icotinib

二代EGFR-TKIs: Afatinib; Dacomitinib; Neratinib; Poziotinib

三代EGFR-TKIs: Osimertinib; Mobocertinib; Rociletinib; Olmutinib; Nazartinib; Alflutinib mesylate; Almonertinib; Lazertinib

四代EGFR-TKIs: EAI045

Anti-EGFR单抗: Cetuximab; Panitumumab; Necitumumab

相关化合物库

FDA-approved Anticancer Drug Library

Anti-cancer Compound Library

Anti-cancer Compound Library-Ⅱ

Anti-cancer Metabolism Compound Library

Cambridge Cancer Compound Library

FDA-approved Drug Library

ADC

c-Met: Telisotuzumab vedotin

HER2: Trastuzumab-Emtansine; Trastuzumab-deruxtecan

HER3: Patritumab deruxtecan

抗血管生成

Vandetanib

Bevacizumab

Ramucirumab

Apatinib

Axitinib

Cabozantinib

Sunitinib

Nintedanib

Sorafenib

免疫检查点抑制剂

PD-1: Pembrolizumab; Camrelizumab; Sintilimab; Nivolumab; Cemiplimab

PD-L1: Atezolizumab; Durvalumab; Avelumab

CTLA-4: Ipilimumab; Tremelimumab

靶向-HER2

Pan-HER TKIs: Afatinib; Neratinib; Dacomitinib

选择性HER2 TKIs: Pyrotinib dimaleate; Poziotinib

Anti-HER2单抗: Trastuzumab; Pertuzumab